Antioxidants Halt Axonal Degeneration in a Mouse Model of X-Adrenoleukodystrophy by López-Erauskin, Jone et al.
ORIGINAL ARTICLE
Antioxidants Halt Axonal Degeneration
in a Mouse Model of
X-Adrenoleukodystrophy
Jone Lo ´pez-Erauskin, MSc,
1,2 Ste ´phane Fourcade, PhD,
1,2 Jorge Galino, MSc,
1,2
Montserrat Ruiz, PhD,
1,2 Agatha Schlu ¨ter, PhD,
1,2 Alba Naudi, PhD,
3 Mariona Jove, PhD,
3
Manuel Portero-Otin, MD, PhD,
3 Reinald Pamplona, MD, PhD,
3 Isidre Ferrer, MD, PhD,
4,5
and Aurora Pujol, MD, PhD
1,2,4,6
Objective: Axonal degeneration is a main contributor to disability in progressive neurodegenerative diseases in
which oxidative stress is often identified as a pathogenic factor. We aim to demonstrate that antioxidants are able to
improve axonal degeneration and locomotor deficits in a mouse model of X-adrenoleukodystrophy (X-ALD).
Methods: X-ALD is a lethal disease caused by loss of function of the ABCD1 peroxisomal transporter of very long
chain fatty acids (VLCFA). The mouse model for X-ALD exhibits a late onset neurological phenotype with locomotor
disability and axonal degeneration in spinal cord resembling the most common phenotype of the disease,
adrenomyeloneuropathy (X-AMN). Recently, we identified oxidative damage as an early event in life, and the excess
of VLCFA as a generator of radical oxygen species (ROS) and oxidative damage to proteins in X-ALD.
Results: Here, we prove the capability of the antioxidants N-acetyl-cysteine, a-lipoic acid, and a-tocopherol to
scavenge VLCFA-dependent ROS generation in vitro. Furthermore, in a preclinical setting, the cocktail of the 3
compounds reversed: (1) oxidative stress and lesions to proteins, (2) immunohistological signs of axonal
degeneration, and (3) locomotor impairment in bar cross and treadmill tests.
Interpretation: We have established a direct link between oxidative stress and axonal damage in a mouse model of
neurodegenerative disease. This conceptual proof of oxidative stress as a major disease-driving factor in X-AMN
warrants translation into clinical trials for X-AMN, and invites assessment of antioxidant strategies in axonopathies in
which oxidative damage might be a contributing factor.
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xidative stress has been said to participate in the
onset and/or progression of neurodegeneration in
human neurological diseases of diverse etiology, including
Parkinson disease, amyotrophic lateral sclerosis, multiple
sclerosis, Alzheimer disease, and Huntington disease, to
cite just a few.
1–5 A common theme in all these diseases is
axonal degeneration, which is seen preceding neuronal cell
body’s death, and might be responsible for much of the
chronic disability.
6,7 Axons are highly vulnerable, as their
unusual size and high metabolic demands render them sus-
ceptible to injury, ischemia, transport defects, and oxida-
tive damage. An indirect link between oxidative stress and
axonal damage in vitro or ex vivo
8 has been suggested in
chemically induced models of oxidative injury.
9,10 How-
ever, a causative role for oxidative stress in axonal degener-
ation in mouse models relevant to human disease has, to
the best of our knowledge, not yet been formally proven.
To address this question, we chose a mouse knockout
lacking ABCD1, a peroxisomal transporter of very long-
chain fatty acids (VLCFA). This is the murine model of X-
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300100), a rare and fatal disease characterized by central
inflammatory demyelination within the central nervous
system or slowly progressive spastic paraparesis, as a conse-
quence of axonopathy in the spinal cord.
11–13 X-ALD is
the most frequently inherited leukodystrophy, with a mini-
mum incidence of 1 in 17,000 males. The gene mutated
in the disease encodes the ABCD1 protein, an adenosine
triphosphate-binding cassette peroxisomal transporter
involved in the import of very long chain fatty acids
(C   22:0) and VLCFA-CoA esters into the peroxisome for
degradation.
14,15 Defective function of the ABCD1 trans-
porter leads to VLCFA accumulation in most organs and
plasma; elevated levels of VLCFA are used as a biomarker
for the biochemical diagnosis of the disease. Classical inac-
tivation of ABCD1 in the mouse results in late onset neu-
rodegeneration with axonopathy in the spinal cord that, in
the absence of inflammatory demyelination in the brain,
resembles the most frequent X-ALD phenotype or adreno-
myeloneuropathy.
16,17 Oxidative damage has been evi-
denced in postmortem brain samples from individuals
with cerebral ALD
18,19 and in mouse spinal cord prior to
disease onset.
20 The source of this oxidative damage is pos-
sibly related to the excess of saturated and unsaturated
VLCFA, shown to generate both free radicals and oxidative
damage to proteins in vitro.
20,21
In the present study, we set out to test the potential
of 3 well-known antioxidants, a-tocopherol, N-acetylcys-
teine (NAC), and a-lipoic acid (LA), first to scavenge
VLCFA-dependent reactive oxygen species production,
and then to ameliorate the neurodegenerative adrenomye-
loneuropathy (AMN)-like phenotype observed in mouse
models of X-ALD. The 3 substances are US Food and
Drug Administration (FDA)-approved drugs shown to be
able to cross the brain–blood barrier and to achieve neu-
roprotective effects in mouse models of neurodegenera-
tion, although their specific effect on axonal degeneration
has not been addressed.
22–24
Materials and Methods
Chemicals
The following chemicals were used: 6-carboxy-20,7 0-dichlorodi-
hydrofluorescein diacetate, diacetoxymethyl-ester (H2-DCFDA)
(Invitrogen, Carlsbad, CA), hexacosanoic acid, C26:0 (Sigma,
St Louis, MO), NAC (Sigma), LA (Sigma), and Trolox (Cal-
biochem, San Diego, CA).
Mouse Breeding
The generation and genotyping of Abcd1
  mice have been previ-
ously described.
16,17,25 Mice used for experiments were of a pure
C57BL/6J background, all male. Animals were sacrificed, and tis-
sues were recovered and conserved at  80 C. All methods
employed in this study are in accordance with the Guide for the
Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-23, re-
vised 1996), and with the ethical committee of The Bellvitge Insti-
tute of Biomedical Research and the government of Catalonia.
Antioxidant Dosage and Treatment of Mice
LA (0.5% wt/wt) and a-tocopherol (1050IU/kg in food) were
mixed into AIN-76A chow from Dyets (Bethlehem, PA).
24,26
NAC (1%) was dissolved in water (pH 3.5).
22 Doses for NAC,
LA, and vitamin E were, respectively, 850mg/kg/day, 430 mg/
kg/day, and 90IU/kg/day (65mg/kg/day). Equivalent doses for
patients have been calculated using the FDA-recommended
scaling factors for a first use in patients (Guidance for Industry:
Estimating the Maximum Safe Starting Dose in Initial Clinical
Trials for Therapeutics in Adult Healthy Volunteers; http://
www.fda.gov/downloads/Drugs/GuidanceComplianceRegulator-
yInformation/Guidances/ucm078932.pdf). For a 70kg patient,
equivalent doses would be 4.8g/day for NAC, 2.4g/day for LA,
and 510IU/day (369mg/day) for vitamin E. Similarly high
doses have already been given to patients in chronic treatments,
with minimal to no side effects reported.
27–30 Combinations of
the antioxidants have also been given without significant inter-
actions or side effects described, although at lower doses.
31,32
For locomotor tests and immunohistological analysis, 12-
month-old animals were randomly assigned to 1 of the following
dietary groups for 6 months. Group I (wild-type [Wt]) mice (n
¼ 12) received only normal AIN-76A chow, Group II (Wt þ
antioxidants [Antx]) Wt mice (n ¼ 9) were treated with chow
containing LA and a-tocopherol and with NAC in drinking
water, Group III Abcd1
 /Abcd2
 /  (Dko) mice (n ¼ 17) received
only normal AIN-76A chow, and Group IV (Dko þ Antx)
Abcd1
 /Abcd2
 /  mice (n ¼ 12) were treated with chow contain-
ing LA and a-tocopherol, and with NAC in drinking water.
For evaluation of oxidative damage and neuropathology,
16-month-old animals were randomly assigned to 1 of the fol-
lowing dietary groups for 6 months. Group I mice (Wt) (n ¼
8) were fed normal AIN-76A chow, Group II mice (Wt þ
Antx) (n ¼ 8) were treated with the antioxidants as above,
Group III mice (Abcd1
 )( n¼ 8) were fed normal AIN-76A
chow, and Group IV mice (Abcd1
 )( n¼ 8) were treated with
antioxidant cocktail as above.
Cell Culture and Treatments
Control and X-ALD human fibroblasts were grown as
described.
20 Intracellular ROS levels were estimated using the
ROS-sensitive H2DCFDA probe as described.
20 Detailed meth-
odology is described in Supplementary Methods.
Control (n ¼ 5) and X-ALD human fibroblasts (n ¼ 5)
were treated in medium containing fetal calf serum (10%) for 24
hours with ethyl alcohol as control, C26:0 (50lM), or antioxi-
dant with C26:0 (50lM). Three different antioxidants were used
at doses previously reported in fibroblasts: Trolox (2mM),
33
NAC (1mM),
34,35 and LA (0.5mM)
34–36; for the higher doses,
Trolox was used at 500nM, NAC at 50lM and LA at 50lM.
The maximum concentration of ethanol used was 2.2%. Ethanol
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were carried out with cells at 95% of confluence, which had a
number of passages ranging from 12 to 15.
Evaluation of Oxidative Lesions
N
e-(carboxymethyl)-lysine (CML), N
e-(carboxyethyl)-lysine
(CEL), and N
e-malondialdehyde-lysine (MDAL) concentrations
in total proteins from spinal cord homogenates or human fibro-
blasts were measured with gas chromatography/mass spectrome-
try (GC/MS), as reported.
20 The amounts of products were
expressedas the ratio of micromole of glutamic semialdehyde,
aminoadipicsemialdehyde, CML, CEL, or MDAL/mol of ly-
sine. Evaluation of direct carbonylation has been performed as
previously described.
37 Detailed methodology is described in
Supplementary Methods.
Immunohistochemistry
Spinal cords were harvested from 22-month-old Wt, Abcd1
 ,
and Abcd1
  mice fed with the cocktail of antioxidants for 6
months, after perfusion with 4% paraformaldehyde as
described.
16,38 Detailed methodology is described in the Sup-
plementary Methods.
Behavioral Testing
TREADMILL TEST. The treadmill apparatus consisted of a
variable speed belt varying in terms of speed and slope. An elec-
trified grid was located to the rear of the belt on which foot
shocks (0.2mA) were administered whenever the mice fell off
the belt. The treadmill apparatus (Panlab, Barcelona, Spain)
consisted of a belt (50cm long and 20cm wide) varying in
terms of speed (5–150cm/s) and slope (0–25 ) enclosed in a
Plexiglas chamber.
39 The latency to falling off the belt (time of
shocks in seconds) and the number of received shocks were
measured. For detailed protocol, see Supplementary Methods.
HORIZONTAL BAR CROSS TEST. Bar cross test was per-
formed as previously described.
38 Detailed methodology is
described in Supplementary Methods.
Statistical Analyses
Data are given as mean 6 standard deviation. Significant differ-
ences were determined by 1-way analysis of variance followed
by Tukey Honestly Significant Difference post-test after verify-
ing normality. For Figure 4G, the number of mice able to per-
form the treadmill test was counted and represented as a per-
centage of mice. Significant differences were determined by chi-
square test. Statistical analyses were performed using the SPSS
12.0 program (SPSS Inc., Chicago, IL).
Results
a-Tocopherol, NAC, or LA Successfully Prevents
Hexacosanoic Acid-Dependent ROS Generation
In Vitro
A consequence of ROS production is their interaction
with biomolecules, in particular DNA, lipids, and pro-
teins, which are then modified and functionally altered.
Proteins can be directly damaged by ROS in a process
called carbonylation, or indirectly damaged by reaction
with active aldehyde products of lipid peroxidation (eg,
malondialdehyde [MDA] or hydroxynonenal) or with
products of glycoxidation, (eg, glyoxal or methylglyoxal),
or as a result of alterations in membrane lipid microen-
vironment secondary to the peroxidative process. In X-
ALD, an increase of markers of lipoxidation (MDA-ly-
sine), combined with markers of glycoxidation and lipox-
idation, CEL and CML, together with markers of direct
carbonylation, can be detected in spinal cords and in pe-
ripheral mononuclear cells or fibroblasts.
20,21 Also, excess
of VLCFA decreases reduced glutathione, and X-ALD
cells are more sensitive to glutathione depletion.
20 Thus,
an ideal antioxidant strategy would combine different
compounds acting through complementary mechanisms
for ROS scavenging.
We chose alpha tocopherol (in the form of its ana-
logue Trolox),
40 as it can inhibit the propagation phase
of the peroxidative process by neutralizing the lipid-
derived radicals; NAC, as it can regenerate reduced gluta-
thione and scavenge several ROS, including OH
˙
,H 2O2,
peroxyl radicals, and nitrogen-centered free radical
41; and
LA, as it can regenerate glutathione from its oxidized
counterpart (oxidized glutathione), ascorbate from dehy-
droascorbate, and a-tocopherol from tocopheryl radi-
cals,
42 thus enhancing the effects of the other 2 com-
pounds. LA and its reduced form, dihydrolipoic acid,
may use their chemical properties as a redox couple to al-
ter protein conformations by forming mixed disulfides,
thus protecting proteins from oxidation. We thus investi-
gated the potential of the 3 agents to scavenge ROS pro-
duction generated by an excess of hexacosanoic acid
(C26:0), as measured using the probe dichlorofluores-
cein. All 3 antioxidants were capable individually of nor-
malizing ROS levels after the addition of 50lM hexaco-
sanoic acid at high but not at low doses (Fig 1). When
combining the antioxidants at low doses, a synergistic
effect was observed, resulting in a full prevention of ROS
accumulation (see Fig 1D).
Combination of a-tocopherol, NAC, and LA
Blocks Oxidative Stress and Damage to
Proteins and DNA in Spinal Cord From
Abcd1
2 Mice
Combined antioxidant therapy is aimed at reproducing
the multistep, combined response that is observed in vivo
leading to recovery after an oxidative challenge.
43 Some
studies have shown that combinations of antioxidants can
be beneficial for pathologies associated with increased
oxidative stress,
44 and that such a strategy might be
ANNALS of Neurology
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treating mitochondriopathies,
45,46 reproducing what is al-
ready present in nature, that is, a combination of antioxi-
dant systems rather than a single system. Thus, we
treated a group of Abcd1
  mice at disease onset (16
months old) with a mixture of the 3 antioxidants for 6
months, and compared spinal cord samples from Wt,
Abcd1
 , and Abcd1
  mice fed with antioxidants (Abcd1
 
þ Antx). We semiquantified carbonyl residues with an
anti-dinitrophenol antibody
37 to find a normalization of
the amount of oxidized proteins when antioxidants were
used (Fig 2A). Further, we quantified by GC/MS the lev-
els of the markers of glycoxidative and lipoxidative
lesions, which were also normalized owing to the antioxi-
dant treatment (see Fig 2B). We had previously observed
that the glutathione peroxidase enzyme GPX-1 is strik-
ingly induced in Abcd1
  spinal cord, reflecting a physio-
logical antioxidant response to increased oxidative
stress.
20 This increase was lowered upon treatment, sug-
gesting that free radicals are scavenged by these com-
pounds (see Fig 2C). As a consequence of oxidative
stress, damage to DNA occurs and is of particular impor-
tance due to the possibility of producing mutations com-
promising cell survival or accelerating aging.
47 We per-
formed immunohistochemistry against the widely used 8-
oxo-7,8-dihydro-20-deoxyguanosine marker (8-oxodG)
48
to observe an increase in labeling in several nuclei of
motoneurons and interneurons (Fig 3A–C and Supple-
mentary Table), thus pinpointing these neuronal subpo-
pulations as plausible first targets for the damage to
FIGURE 1: Trolox, N-acetylcysteine and a-lipoic acid (LA) prevent radical oxygen species (ROS) generated by C26:0. Intracellu-
lar ROS was measured in control (n 5 5) and X-adrenoleukodystrophy (X-ALD) human fibroblasts (n 5 5) after 24 hours. Three
different antioxidants were used at high doses: (A) Trolox, (B) N-acetylcysteine (NAC), and (C) LA. (D) The 3 antioxidants were
used alone or in combination at lower doses. Significant differences were determined as described in Materials and Methods
(*p < 0.05, **p < 0.01, ***p < 0.001). EtOH 5 ethyl alcohol; ANTX 5 antioxidants.
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agreement with the detected upregulation of catalase in
these cell types, as described.
20 The combination of anti-
oxidants used successfully diminished the labeling of
motoneurons and interneurons with 8-oxodG antibody
as compared to untreated Abcd1
  mice (see Fig 3A–C
and Supplementary Table).
Treatment with a-Tocopherol, NAC, and LA
Initiated after Disease Onset Rescues Axonal
Degeneration in X-ALD Mouse Models
Furthermore, we investigated the effects of the treatment
on the neurodegenerative phenotype exhibited by X-ALD
mouse models. Abcd1
  mice present an overt neuropath-
ological phenotype at 22 months of age, characterized by
axonal damage, as suggested by the accumulation of amy-
loid precursor protein (APP) and synaptophysin in axo-
nal swellings. This is accompanied by scattered myelin
debris, as revealed by Sudan black, and astrocytosis and
microgliosis, as identified with glial fibrillary acidic pro-
tein (GFAP) and lectin staining, respectively, without
signs of apoptosis (see Fig 3D–S and Supplementary Ta-
ble).
16 The first abnormal deposition of synaptophysin is
seen at around 12 months of age, earlier than
FIGURE 2: Antioxidant treatment normalizes oxidative
lesions markers in spinal cord from 22-month-old Abcd1
2
mice. (A) Dinitrophenol (DNP) levels in 22-month-old wild-
type (Wt), Abcd1
2, and Abcd1
2 1 antioxidants (Antx) mice.
The quantification of these blots by densitometry was per-
formed and normalized to c-tubulin. (B) N
e-(carboxymethyl)-
lysine (CML), N
e-(carboxyethyl)-lysine (CEL), and N
e-malon-
dialdehyde-lysine (MDAL) in Wt, Abcd1
2, and Abcd1
2 1
Antx mice. (C) GPX1 levels were quantified in Wt, Abcd1
2,
and Abcd1
2 1 Antx mice. Significant differences were
determined as described in Materials and Methods (n 5 6
mice per genotype and condition; *p < 0.05, **p < 0.01,
***p < 0.001).
FIGURE 3: Oxidative stress, myelin, and axonal pathologies
in 22-month-old Abcd1
2 spinal cord are prevented by an
antioxidant cocktail. Longitudinal sections of the dorsal spi-
nal cord in wild-type (Wt) (A, D, G, J, M, P), Abcd1
2 (B, E,
H, K, N, Q) and Abcd1
2 1 antioxidants (Antx) (C, F, I, L, O,
R) mice were processed for 8-oxo-7,8-dihydro-20-deoxygua-
nosine marker (8-oxodG) (A–C), lectin Lycopersicon esculen-
tum (D-F), glial fibrillary acidic protein (GFAP) (G–I),
synaptophysin (J–L), amyloid precursor protein (APP) (M–O),
and Sudan black (P–R). Bar 5 25lm. (S) Quantification of
APP and synaptophysin accumulation in axonal swellings in
Wt, Abcd1
2, and Abcd1
2 1 Antx mice. Significant differen-
ces were determined as described in Materials and Methods
(n 5 5–6 mice per genotype and condition; **p < 0.01).
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and the accompanying reactive glial changes are the py-
ramidal tracts and dorsal fascicles. After 6 months of
antioxidant diet started at 16 months of age, we observed
that axonal damage as measured by quantifying APP and
synaptophysin deposition was strikingly reduced to con-
trol levels (see Fig 3D–S and Supplementary Table).
Also, the number of reactive astrocytes and reactive
microglia was reduced, but not the total numbers of
astrocytes and microglia. These results suggest that oxida-
tive damage control halts axonal degeneration in the
mouse model used.
Antioxidant Therapy Prevents and Arrests
Progression of Locomotor Deficits in
Abcd1
 /Abcd2
 /  Mice
We chose a double mutant Abcd1/abcd2, a model in
which the transporters of both homologs have been
deleted by classical gene targeting.
16,17,38,49 As the 2 pro-
teins share overlapping functions in vivo in the metabo-
lism of fatty acids,
38,50 double mutants exhibit higher
VLCFA accumulation in spinal cord,
16 higher levels of
oxidative damage to proteins,
21 and a more severe AMN-
like pathology, with an earlier onset than is the case with
the single mutant Abcd1. Synaptophysin and abnormal
accumulation of APP in damaged axons are the earliest
immunohistological markers, evidenced from 12 months
onward, at a level of pathology comparable to the 22-
month-old Abcd1 knockouts.
16,38 Also, locomotor testing
is facilitated in this model, as the first signs of neurologi-
cal involvement can be seen at 15 months of age, using
the bar cross test.
38 For the sake of starting the treatment
on symptomatic mice, we re-evaluated locomotor skills
by using the bar cross
38 and treadmill tests,
39 starting at
12 months of age. Confirming previous results at 15
months, the Abcd1/Abcd2 null mice presented abnormal
scores as they required more time to reach a platform
along the bar. Double mutants also exhibited a marked
tendency to slip off the bar, as a sign of ataxia present in
the pretreatment phase (Fig 4A, B). The treadmill test
was not sensitive enough to detect abnormalities at that
age, however (see Fig 4E, F).
We thus launched a preclinical trial with 4 groups
of mice, Wt on vehicle or oral antioxidants, and double
mutants on vehicle or antioxidants, and treated them for
6 months starting at 12 months of age. At the end of
treatment, beneficial effects of antioxidants were striking,
reaching full normalization of the time used to cross the
bar and the number of slips (see Fig 4C, D and Supple-
mentary Figs 1 and 2). Double mutants on normal chow
presented with postural hypotonia and ataxia. Seventy to
80% of these double mutants had severe difficulties
standing on their 4 limbs on the bar; they wrapped their
hind and fore limbs around the bar instead, and used
their fore limbs to drag themselves along the beam.
Trembling was also very frequently noticed; these were
features also visible in older (22–24 month) single Abcd1
null mice, and might mirror the spastic paraparesis and
ataxic gait that X-AMN patients suffer. These phenotypic
abnormalities were absent in mice that received the anti-
oxidant treatment. In the treadmill test, at a belt speed
of 30cm/sec and 20  slope, differences were detected in
Abcd1/abcd2 compared to Wt mice. The number of mice
FIGURE 4: A combination of antioxidants rescues locomotor
deficits in Abcd1
2/Abcd2
2/2 mice. Bar cross test (A–D) and
treadmill experiment (E–I) were carried out at 12 and 18
months of age (wild-type [Wt; n 5 12], Wt 1 antioxidants
[Antx; n 5 9], Abcd1
2/Abcd2
2/2 [Dko; n 5 17], and
Abcd1
2/Abcd2
2/2 1 Antx [Dko 1 Antx; n 5 12]). The time
spent to cross the bar (A, C) and the number of slips (B, D)
were quantified at 12 (A, B) and 18 months of age (C, D).
Treadmill experiments were performed in Wt and Dko mice
at 12 (E, F) and 18 months of age (G, I). Number of shocks
(E, H) and latency to falling off the belt (time of shocks in
seconds) (F, I) were quantified after 7 minutes. The percent-
age of mice still running/minute is represented panel G. Sig-
nificant differences were determined as described in
Materials and Methods (*p < 0.05, **p < 0.01, ***p <
0.001).
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At minute 6, only 60% of Abcd1/abcd2 mice were able
to continue running, whereas all Wts were still on the
treadmill (see Fig 4G). In addition, at the end of the
experiment a higher cumulative number and duration of
shocks (see Fig 4H, I) was observed in the mutant ani-
mals. Upon treatment, all Abcd1/abcd2 mice were able to
perform the test until the end, and were indistinguishable
from Wts or from Wts fed with antioxidants regarding
number of shocks and cumulative time (see Fig 4G–I).
Immunohistological analysis demonstrated full recovery
of axonal degeneration features as measured by APP and
synaptophysin staining, and decrease of activated astro-
cytes and microglia (Supplementary Fig 3 and Supple-
mentary Table). Taken together, our results provide com-
pelling evidence for a beneficial effect of a long trial with
a combination of a-tocopherol, NAC, and LA in revers-
ing oxidative lesions at the cellular and tissue level,
arresting axonal damage, and rescuing the locomotor
neurological abnormalities in mouse models of X-ALD.
Discussion
We have previously suggested that oxidative damage,
because of its early appearance in the disease cascade and
its direct relationship with the accumulation of VLCFA,
could be a contributing factor to X-ALD disease patho-
genesis.
20 The work presented here indicates that the
cocktail of antioxidants used efficaciously reverses the
oxidative damage to proteins in whole spinal cords, and
also specifically on DNA of spinal motoneurons and
interneurons. Chronic DNA damage leads to accelerated
aging,
47 and is readily detected at 3.5 months of age in
these cell types, together with increased catalase immuno-
staining,
20 thus suggesting a plausible origin for the axo-
nal degenerative process that is evidenced much later in
life.
Furthermore, we present compelling evidences that
the chosen antioxidant combination halted clinical pro-
gression and reversed axonal damage in the mouse
model, thus providing the formal conceptual proof for
oxidative injury or at least an antioxidant-sensitive pro-
cess as a main etiopathogenic factor in this disease. This
constitutes a novel finding, as oxidative stress and dam-
age are involved in a wide variety of neurological dis-
eases,
2 and thus have been classically considered common
and simply epiphenomenal events in the neurodegenera-
tive cascade that occurs in the late stages of the disorders.
This concept has been reinforced by the general lack of
therapeutic effects of antioxidants in randomized clinical
trials, which might indicate that oxidative stress would
not constitute a major contributor to disease pathology,
at least at the stage when the treatment was applied.
However, exceptions can be made when the causality link
between oxidative stress and disease is well established, as
is the case for Friedreich ataxia, a rare disease caused by
mutations in frataxin, a mitochondrial ferrosulfur protein
involved in ROS homeostasis.
51 Friedreich patients ex-
hibit spinocerebellar ataxia with dorsal root ganglia
degeneration.
52,53 Clinical trials using high doses of the
antioxidant idebenone, a coenzyme Q10-related mole-
cule, have demonstrated that this compound is able to
improve both cardiac hypertrophy and neurological
symptoms associated with the disease.
54,55 In contrast,
low doses of idebenone failed to render neurological ben-
efits in similar clinical settings,
56 suggesting a critical
issue regarding the appropriate dose, perhaps hampering
positive outcomes in other studies.
Although externally added oxidant insults have been
shown to produce axonal degeneration in culture,
10 ad i s -
ease-relevant murine model for axonal damage, caused by
endogenously produced oxidative stress, was lacking until
now. Thus, the Abcd1 null mouse appears to be a useful
model for dissecting the molecular and cellular changes
underlying oxidative stress-dependent axonal pathology, in
so doing providing insights into the cascade of events that
cause irrevocable nerve cell degeneration. Importantly, the
model provides a long window of opportunity for inter-
vention, during which the initial axon dysfunction has not
yet progressed to frank degeneration. Targeted strategies to
ameliorate these axonal changes may provide a new
approach to delaying the cascade of intracellular changes
in other diseases with axonal damage.
Our data strongly suggest that an early and care-
fully tailored antioxidant intervention using the cocktail
described could be a plausible therapeutic option for X-
AMN patients, who do not suffer from severe neuroin-
flammatory demyelination. Biological effects could be
easily monitored by quantitative measurement of bio-
markers of oxidative damage in the peripheral blood
mononuclear cells in X-AMN patients, as previously
shown.
21 Therapeutic implications derived from this
work could be extrapolated to other diseases that share
both axonal degeneration as a significant component of
clinical progression and oxidative stress as a main or early
contributing pathogenic factor.
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